

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



山東新華製藥股份有限公司

Shandong Xinhua Pharmaceutical Company Limited

(a joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 00719)

UNAUDITED FIRST QUARTER RESULTS OF 2026

(for the period from 1 January 2026 to 31 March 2026)

This announcement is made pursuant to rules 13.09 and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Board**”) of Shandong Xinhua Pharmaceutical Company Limited (the “**Company**”) hereby announces the unaudited consolidated results of the Company and its subsidiaries (the “**Group**”) for the three calendar months ended 31 March 2026. The financial information set out in this announcement has been prepared in accordance with the CASBE (as defined under the Listing Rules) and has been reviewed and approved by the audit committee of the Board.

Members of the Board, members of senior management and the persons in charge of the accounting function of the Company (i) warrant that there is no false representation or misleading statement contained in, or material omission from, this announcement; and (ii) jointly and severally accept legal responsibility for the accuracy and completeness of the information contained in this announcement.

This announcement is simultaneously made available on the website of The Stock Exchange of Hong Kong Limited at <https://www.hkexnews.hk> and the website of the Company at <https://www.xhzy.com>. The first quarterly report of 2026 prepared in accordance with the CASBE will also be available at <http://www.cninfo.com.cn>.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

This announcement was prepared in both Chinese and English. In the event of any inconsistency between the two versions, the Chinese version shall prevail.

I. KEY ACCOUNTING AND FINANCIAL DATA

Item	January to March 2026 (Unaudited) RMB Yuan	January to March 2025 (Unaudited) RMB Yuan	Change as compared to the same period of last year
Operating income	2,423,049,619.10	2,429,825,335.81	(0.28%)
Net profit attributable to shareholders of listed company	83,903,044.36	112,095,257.24	(25.15%)

Net profit attributable to shareholders of listed company after deduction of non-recurring profit and loss items	80,291,736.33	105,028,074.41	(23.55%)
Net cash flow from operating activities	(116,552,703.09)	8,425,190.10	(1,483.38%)
Basic earnings per share (RMB Yuan / Share)	0.12	0.15	(20.00%)
Diluted earnings per share (RMB Yuan / Share)	0.12	0.15	(20.00%)
Weighted average return on net assets (%)	1.59%	2.21%	Decreased by 0.62 percentage points
Item	As at 31 March 2026 (Unaudited) RMB Yuan	As at 31 December 2025 (Audited) RMB Yuan	Change as compared to the end of last year
Total assets	9,068,927,951.77	9,185,695,768.16	(1.27%)
Net assets attributable to the shareholders of listed company	5,349,787,689.69	5,208,753,244.52	2.71%

II. PROFIT AND LOSS ACCOUNT

Item	January to March 2026		January to March 2025	
	Consolidated (Unaudited) RMB Yuan	Parent company (Unaudited) RMB Yuan	Consolidated (Unaudited) RMB Yuan	Parent company (Unaudited) RMB Yuan
I. Gross revenue	2,423,049,619.10	990,379,467.30	2,429,825,335.81	1,065,099,659.59
Including: Operating revenue	2,423,049,619.10	990,379,467.30	2,429,825,335.81	1,065,099,659.59
II. Total operating costs	2,313,460,629.83	903,942,414.71	2,299,988,387.70	939,482,197.17
Including: Operating costs	1,981,945,053.94	731,289,010.24	1,974,290,313.61	768,234,413.12
Taxes and surcharges	22,865,468.49	15,463,144.01	17,878,928.90	11,274,769.56
Selling expenses	103,476,027.03	9,083,606.88	99,952,491.15	7,486,994.78
Administration expenses	94,907,605.70	66,757,877.76	94,042,826.77	64,868,908.15
Research and development (R&D) costs	95,473,864.96	68,426,979.48	109,788,595.18	84,588,682.81
Financial expenses	14,792,609.71	12,921,796.34	4,035,232.09	3,028,428.75
Including: Interest expense	8,449,572.07	7,386,390.04	10,945,223.03	9,636,137.73
Interest income	1,165,719.39	1,190,710.43	2,409,858.79	2,039,136.15
Add: Other income	8,951,288.61	6,527,378.86	12,233,676.46	9,769,170.02
Investment income (losses to be listed with brackets)	333,529.89	333,529.89	(760,243.82)	(760,243.82)
Including: Investment income from associates and joint ventures (losses to be listed with brackets)	333,529.89	333,529.89	(760,243.82)	(760,243.82)
Credit impairment loss (losses to be listed with brackets)	50,250.00	-	100,000.00	-
Assets impairment loss (losses to be listed with brackets)	-	-	-	-
Gains from asset disposal (losses to be listed with brackets)	108,900.17	95,805.45	1,760,884.21	1,643,456.33
III. Operating profits (losses to be listed in brackets)	119,032,957.94	93,393,766.79	143,171,264.96	136,269,844.95

Add: non-operating income	676,607.62	572,750.37	325,013.26	278,917.79
Less: non-operating expenses	1,076,787.65	430,350.91	806,901.64	563,484.24
IV. Total profits (total loss to be listed with brackets)	118,632,777.91	93,536,166.25	142,689,376.58	135,985,278.50
Less: income tax expense	35,365,534.05	13,980,395.47	27,045,573.46	20,511,828.35
V. Net profits (net loss to be listed in brackets)	83,267,243.86	79,555,770.78	115,643,803.12	115,473,450.15
(I) According to operation continuity				
1. Net profit from continued operations (net losses to be listed in brackets)	83,267,243.86	79,555,770.78	115,643,803.12	115,473,450.15
2. Net profit from discontinued operations (net losses to be listed in brackets)		-	-	-
(II) According to ownership				
1. Net profit attributable to shareholders of parent company	83,903,044.36	-	112,095,257.24	-
2. Minority interest income or loss	(635,800.50)	-	3,548,545.88	-
VI. Net amount of other comprehensive income after tax	(23,698,036.77)	(22,231,580.00)	(10,645,120.96)	(10,395,622.40)
Net amount of other comprehensive income after tax attributable to the shareholders of parent company	(23,434,398.84)	-	(10,573,077.19)	-
(I) Other comprehensive income not subject to reclassification to profit or loss	(22,231,580.00)	(22,231,580.00)	(10,395,622.40)	(10,395,622.40)
Changes in fair value of other equity instruments investment	(22,231,580.00)	(22,231,580.00)	(10,395,622.40)	(10,395,622.40)
(II) Other comprehensive income to be reclassified to profit or loss	(1,202,818.84)	-	(177,454.79)	-
Conversion difference of foreign currency statement	(1,202,818.84)	-	(177,454.79)	-
Net amount of other comprehensive income after tax attributable to the minority shareholders	(263,637.93)	-	(72,043.77)	-
VII. Total comprehensive income	59,569,207.09	57,324,190.78	104,998,682.16	105,077,827.75
Total comprehensive income attributable to the shareholders of parent company	60,468,645.52	-	101,522,180.05	-
Total comprehensive income attributable to the minority shareholders	(899,438.43)	-	3,476,502.11	-
VIII. Earnings per share:				
(I) Basic earnings per share	0.12	-	0.15	-
(II) Diluted earnings per share	0.12	-	0.15	-

III. CHANGES IN ACCOUNTING POLICIES

Contents and reasons of accounting policy changes	Approval processes	Notes
<p>The Ministry of Finance issued the interpretation of accounting standards for Business Enterprises No. 19 (hereinafter referred to as “Interpretation No. 19”) on 5 December 2025.</p> <p>Interpretation No. 19 contains updates in relation to “Accounting Treatment of Compensatory Assets in Business Combinations under Non Common Control”, “Accounting Treatment of Related Capital Reserves when Disposing of Subsidiaries Obtained through Business Combinations under Common Control”, “Derecognition of Financial Liabilities Settled by Electronic Payment Systems”, “Evaluation and Disclosure of Cash Flow Characteristics of Financial Asset Contracts”, and “Disclosure of Equity Instruments Designated as Measured at Fair Value with Changes Recognized in Other Comprehensive Income”, and became effective on 1 January 2026.</p> <p>The Company changed its current accounting policies in accordance with the requirements of Interpretation No. 19 accordingly.</p>	<p>Relevant accounting policy changes were approved at the tenth meeting of the 11th Board of the Company on 27 March 2026.</p>	<p>The changes in relevant accounting policies have no significant impact on the Group’s financial statements.</p>

By Order of the Board
Shandong Xinhua Pharmaceutical Company Limited
He Tongqing
Chairman

28 April 2026, Zibo, People’s Republic of China

As at the date of this announcement, the Board comprises:

Executive Directors:

Mr. He Tongqing (Chairman)
Mr. Xu Wenhui
Mr. Hou Ning

Non-executive Director:

Mr. Zhang Chengyong

Independent Non-executive Directors:

Mr. Pan Guangcheng
Mr. Zhu Jianwei
Mr. Ling Peixue
Ms. Cheung Ching Ching, Daisy